Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27766807 | 1.00 | CYP19A1 (0.40) | CYP19A1SLC9A1 | |
| SCHEMBL2820399 | 0.73 | CYP19A1 (0.46) | CYP19A1 | |
| SCHEMBL2822126 | 0.73 | CYP19A1 (0.46) | CYP19A1 | |
| SCHEMBL28065635 | 0.70 | CYP19A1 (0.49) | CYP19A1 | |
| Hydrochloric Acid SCHEMBL10651502 | 0.69 | CYP19A1 (0.49) | CYP19A1 | |
| SCHEMBL2818470 | 0.69 | MAOA (0.36) | SLC9A1 | |
| SCHEMBL11236680 | 0.69 | CYP19A1 (0.44) | CYP19A1 | |
| SCHEMBL11559534 | 0.67 | CYP19A1 (0.56) | CYP19A1 | |
| SCHEMBL2817709 | 0.65 | CYP19A1 (0.46) | CYP19A1 | |
| SCHEMBL2818454 | 0.65 | CYP19A1 (0.46) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436035-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| EP-2213668-A2 | Imidazoles as aldosterone synthase inhibitors | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| CN-101605777-A | Imidazoles as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2009-12-16 | — | — | CN | disclosed |
| EP-2094680-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008076336-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048562-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP17A1 | CYP19A1 11/4885SLC9A1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.